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Abstract
Drug susceptibility testing of Mycobacterium tuberculosis in the diagnostic laboratory classiﬁes clinical isolates as either drug-‘resistant’
or drug-‘susceptible’, on the basis of their ability to grow in the presence of a ‘critical concentration’ of the test compound. From
knowledge of the mechanisms that underlie drug resistance, it has become evident that drug resistance in M. tuberculosis is quite hetero-
geneous and involves low-level, moderate-level and high-level drug resistance phenotypes. Different mutations are associated with differ-
ent levels of phenotypic resistance, and the acquisition of a genetic alteration leading to a decrease in drug susceptibility does not
inevitably exclude the affected compound from treatment regimens. As a result, the simple categorization of clinical M. tuberculosis iso-
lates as ‘resistant’ on the basis of susceptibility testing at ‘critical concentrations’ may need to be revised and supplemented by quantita-
tive measures of resistance testing to reﬂect the biological complexity of drug resistance, with the view of optimally exploiting the
compounds available for treatment.
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Our head is round to allow thought to change direc-
tion. Francis Picabia
As one of the leading causes of death from curable infectious
diseases, tuberculosis (TB) is a serious global health issue.
The high rates of TB incidence and prevalence in developing
countries have a considerable impact on population-level
morbidity and mortality, particularly in settings where human
immunodeﬁciency virus incidence rates are high [1]. The cur-
rent situation is characterized by an alarming emergence of
drug resistance, and much attention has been focused on the
burden of multidrug-resistant (MDR) and extended drug-
resistant (XDR) TB [2].
In the diagnostic laboratory, drug susceptibility testing of
Mycobacterium tuberculosis is notably different from standard
procedures in clinical microbiology, where a series of drug
dilutions is used to determine the minimal drug concentra-
tion (the MIC) required to inhibit bacterial growth in vitro.
Currently established procedures for susceptibility testing
of M. tuberculosis classify clinical isolates as either drug-
‘resistant’ or drug-‘susceptible’, on the based of their ability
to grow in the presence of a (mostly single) ‘critical drug
concentration’ (Table 1). On the basis of a 1963 WHO
document, the critical concentration is deﬁned as the low-
est concentration of drug that inhibits ‡95% of wild-type
strains of bacilli that have not been exposed to the drug
previously. ‘Resistance is deﬁned as a decrease in sensitivity
of sufﬁcient degree to be reasonably certain that the strain
concerned is different from a sample of wild strains of
human type that have never come into contact with the
drug. This deﬁnition is based on laboratory testings; strains
that are resistant in this sense do not necessarily fail to
respond’ [3]. Thus deﬁned, the critical concentration is an
epidemiological parameter used to distinguish ‘wild-type’
strains from ‘non-wild-type’ strains that are able to grow
in the presence of higher drug concentrations; it corre-
ª2011 The Author
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/j.1469-0691.2011.03551.x
sponds to what is deﬁned as the epidemiological cut-off
[4]. The ‘critical concentration’ often bears little relation-
ship to the drug concentrations present in vivo (Table 1),
and its accuracy in predicting clinical failure may, in part,
be limited [5–7].
During the past 20 years, signiﬁcant knowledge has been
gained concerning the molecular mechanisms of mycobacte-
rial drug resistance (http://www.tbdreamdb.com). These
studies have established, unequivocally, that the chromo-
somal loci responsible for resistance to various drugs are
not linked. Thus, polydrug or multidrug resistance in
M. tuberculosis is not caused by a single genetic locus, such as
upregulation of an efﬂux pump or induction of a transcrip-
tional regulator, but rather by an accumulation of multiple
different mutations. These studies have also established that
drug resistance in M. tuberculosis is by no means a homoge-
neous biological entity, but, on the contrary, is quite hetero-
geneous.
In particular, various levels of phenotypic drug resistance
are found in M. tuberculosis—low-level, moderate-level and
high-level drug resistance—and these different levels of phe-
notypic drug resistance are associated with distinct genetic
mechanisms (Table 2). In general, there is a clear correlation
between the genetic mechanism and the resistance pheno-
type. Thus, mutations in rpsL (streptomycin), rpoB (rifampin)
or 16S rRNA (2-deoxystreptamine aminoglycosides) are
associated with high-level drug resistance, whereas mutations
in gldB (streptomycin), eis (kanamycin) and inhA (isoniazid)
confer a low-level resistance phenotype (Fig. 1). In addition,
depending on the speciﬁc mutation, an altered resistance
TABLE 1. Mycobacterial drug sus-
ceptibility testing: the critical con-
centration Antimicrobial
agent
MIC (mg/L) of
susceptible
Mycobacterium
tuberculosisa
Concentration
(mg/L) in serumb
Concentration (mg/L)
used for testingc
Low High
Isoniazid 0.05–0.2 5–10 0.1 0.4
Rifampin 0.5 10 2 –
Pyrazinamide 20 40–50 100 –
Ethambutol 1–5 2–5 2.5 7.5
Oﬂoxacin 0.25–0.5 2–10 2 –
Ethionamide 0.5–2.5 2–20 1.25 –
Streptomycin 0.5–1.0 25–50 2 6
Amikacin 0.5–1.0 20–40 1 –
Capreomycin 2–5 10–30 5 –
aMIC of wild-type M. tuberculosis.
bConcentrations 1–4 h after usual dosage.
cDrug concentration (‘critical concentration’) used for testing in the diagnostic laboratory; these concentrations may
differ slightly for different media, e.g. BACTEC broth, 7H10 medium, and 7H11 medium.
TABLE 2. Mechanisms of drug resis-
tance in Mycobacterium tuberculosis
Drug
Gene(s)
involved in
resistance
Role in
resistance Phenotypic resistance
Isoniazid katG Prodrug
conversion
Moderate to high level (always >1 mg/L) [11,29,30]
inhA Drug target Mostly low level (<1 mg/L) [11,29,30]
Rifampin rpoB Drug target Mostly high level, rarely low level (dependent on mutation)
[8,9,11,31,32]
Pyrazinamide pncA Prodrug
conversion
Mostly high level [14]
Ethambutol embB Drug target Low to moderate level [11,33,34]
Streptomycin rpsL Drug target High level [35,36]
rrs Drug target Moderate level [35–37]
gldB Drug target Low level [38]
Kanamycin rrs Drug target Mostly high level (dependent on mutation) [39–44]
eis Drug Low level [45,46]
Capreomycin rrs Drug target Variable (dependent on mutation) [42,43,47] (F.A. Sirgel,
M. Tait, R.M. Warren, E.M. Streicher, N.C. Gey van Pittius,
G. Coetzee, P.D. van Helden, E.C. Bo¨ttger, E.Y. Hoosain,
M. Chabula-Nxiweni, C. Hayes, T.C. Victor, A. Trollip,
Unpublished data)
tlyA Drug target Low level [48]
Fluoroquinolones gyrA Drug target Low to moderate level (dependent on mutation) [16,17]
(F. A. Sirgel, R. M. Warren, P. D. van Helden, E. C. Bo¨ttger,
manuscript in preparation)
gyrB
Ethionamide inhA Drug target Low to moderate level [49]
ethA Prodrug
conversion
Moderate to high level [49]
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locus may result in different phenotypes; for example, most
mutations in rpoB result in high-level rifampin resistance,
whereas rare mutations also exist that confer a low-level
resistance phenotype [8,9].
Clinical isolates may display a highly restricted number of
resistance-conferring chromosomal alterations in a drug tar-
get gene. Presumably, this reﬂects the in vivo selection for
resistance mutations that maintain gene function, readily
explaining the predominance of certain resistance mutations,
e.g. RpsL Lys42 ﬁ Arg (streptomycin), KatG Ser315 ﬁ Thr
(isoniazid), and 16S rRNA 1408A ﬁ G (kanamycin and
amikacin). In contrast, resistance-conferring chromosomal
alterations in genes involved in prodrug conversion, e.g. pncA
and ethA, often display a broad diversity, indicating that there
is little functional constraint, as a loss of gene function phe-
notype is apparently well tolerated (for reviews, see [7,10]).
Intuitively, a strain’s overall genomic background—i.e. nucleic
acid sequence polymorphisms and unknown altera-
tions—would be expected to affect the phenotype of a chro-
mosomal resistance determinant. It is therefore perhaps
surprising that the resistance level associated with a deﬁned
resistance mutation is a rather stable characteristic. Pheno-
typic resistance heterogeneity reﬂects the different genetic
resistance mechanisms—with each given mutational alter-
ation being associated with a distinct phenotypic resistance
level. Signiﬁcant levels of phenotypic heterogeneity for a
given resistance mutation have so far been observed only
rarely, e.g. the katG Ser315 ﬁ T alteration and isoniazid
resistance [7,11].
Depending on the Gaussian distribution of MIC levels
associated with deﬁned resistance mechanisms, separation
into low-level, moderate-level and high-level resistance may
be clear-cut with deﬁned boundaries, or more reminiscent
of a resistance continuum. Cumulative percentage diagrams
can be used to describe the epidemiology of resistance to
any speciﬁc compound. Such a cumulative percentage plot is
the result of two factors: (i) the distribution of MIC levels
associated with different resistance mechanisms; and (ii) the
frequency of the different resistance mechanisms’ presence
in the population (Fig. 2). For several anti-TB compounds,
including isoniazid, streptomycin, kanamycin, and capreomy-
cin, a low-level resistance phenotype is both deﬁned as a dis-
tinct genetic entity and clearly separated by quantitative
measures of drug susceptibility from a high-level resistance
phenotype. This was ﬁrst recognized in the mid-1990s for
streptomycin and isoniazd [12,13]. Drug concentrations that
will overcome this phenotype of decreased drug susceptibil-
ity are readily obtained in vivo (Table 1), indicating that
low-level drug resistance may not correspond to clinical
resistance [14,15]. For other anti-TB compounds, such as
ethambutol and quinolones, a clear-cut separation into dis-
tinct resistance levels, each associated with a distinct genetic
resistance mechanism, is not observed in clinical strains.
Here, resistance is apparently attributable mostly to a single
genetic resistance mechanism affecting the drug target and
associated with low to moderate levels of drug resis-
tance—mutations in embB (ethambutol) or mutations in gyrA
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FIG. 1. Schematized changes in drug susceptibility upon mutational
alterations—exemplary Gaussian distributions of population proﬁles.
= ’critical concentration’; = drug serum level.
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(quinolones), respectively. The clinical implications of embB
mutations are currently unclear [11]. On the other hand,
mutations in gyrA typically result in low to moderate levels
of quinolone resistance [16,17], and these are presumably
sufﬁcient to confer clinical resistance to oﬂoxacin. However,
circumstantial evidence has been provided that, owing to
more favourable MICs associated with the corresponding
mutations, the later-generation ﬂuoroquinolones, such as
moxiﬂoxacin, may still improve treatment outcome [18,19].
Unfortunately, despite the intricacies discussed above,
these different levels of phenotypic resistance are not taken
into account when ‘critical concentrations’ are used for
mycobacterial in vitro drug susceptibility testing. As a result
of this procedure, an isolate will be categorized uniformly as
resistant in the diagnostic laboratory regardless of whether
high-level, moderate-level or low-level drug resistance is
present. However, the biological implications of low-level vs.
high-level drug resistance are different, for a number of rea-
sons, and not least because in vivo drug concentrations need
to be taken into account. In other words, the resistance lev-
els determined in vitro should be related to the drug concen-
trations that can be achieved in vivo. Peak serum levels of
isoniazid, rifampin and aminoglycosides are much higher than
the MIC. Conversely, peak serum levels of oﬂoxacin, etham-
butol and ethionamide are close to MIC values. As a result,
drug levels may remain subinhibitory for the latter com-
pounds during much of treatment, in particular when muta-
tions that further decrease drug susceptibility are present.
Laboratory MIC data and pharmacokinetic (PK) modelling
can be used to calculate PK/pharmacodynamic (PD) charac-
teristics and to provide measures of drug bioavailability, such
as area under the curve over MIC, the maximum concentra-
tion over MIC, and the time above MIC [4,20]. PK/PD char-
acteristics allow us to tentatively suggest breakpoints, but
they cannot be directly linked to clinical outcome. In
addition, therapy for TB comprises a combination of three
or four drugs administered simultaneously. Thus, whereas
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FIG. 2. Schematized drug-resistant populations and cumulative per-
centage plots of resistant strains. (a) Well-separated populations
with low-level ( ) and high-level ( ) drug resistance, each associ-
ated with a different genetic resistance mechanism. (b) Two different
genetic resistance mechanisms ( and ) are associated with dif-
ferent phenotypic resistance levels, but there is not a deﬁned cut-off
separating the two. (c–f) Cumulative percentage diagrams of strains
with various levels of phenotypic resistance. Scenarios (c)–(f) assume
two different mechanisms of resistance, which may (c) or may not
(f) be well separated from each other. The cumulative percentage
plot is a result of the distribution of MIC levels associated with each
resistance mechanism and the frequency of the resistance mecha-
nisms in the population.
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in vitro drug susceptibility results apply to each of the drugs
in the combination, and not to the entire regimen, the out-
come of anti-TB therapy is a composite outcome, owing to
the use of multiple drugs. The efﬁcacies of non-antagonistic
drugs in combination therapy will be at least additive, effec-
tively reducing the MIC [21]. Thus, depending on PK/PD
indices, sufﬁciently high drug concentrations may be achieved
in vivo, despite low-level or moderate-level drug resistance
in vitro.
Standardized treatment regimens for MDR TB are possi-
ble, and may result in good clinical outcome. However, treat-
ment of XDR TB is much more problematic [22–26]. For
both MDR TB and XDR TB, reliable and robust data on drug
resistance are required for correct diagnosis and choice of
the proper therapeutic regimen, so as not to result in thera-
peutic failure, further dissemination, and ampliﬁcation of
resistance [27]. With the global rise in MDR strains, there is
an increasing need to determine susceptibility to ﬁrst-line
and second-line anti-TB agents precisely. Treatment of
patients with drug-resistant TB should be based on reliable
and quantitative measures of susceptibility testing, a corner-
stone for preventing further ampliﬁcation of resistance and
for optimally exploiting the available compounds. However,
even in the developed countries, only a limited panel of anti-
TB drug concentrations is tested, leaving the exact resistance
levels of clinical M. tuberculosis isolates in part unexplored. In
principle, automated systems for cultural propagation of
mycobacteria have the potential to meet the challenge of pre-
cise determination of drug resistance levels with reasonable
labour input. For this purpose, we have recently adopted a
fully automated platform by combining commercially available
instrumentation (using a ﬂuorescence-based oxygen sensor
for growth detection) with software developed by the manu-
facturer according to our speciﬁcations [28]. This procedure
provides a fully automated walk-away system for semiquantita-
tive drug susceptibility testing of M. tuberculosis, equipped with
an expert system for interpretation.
Limitations in mycobacterial drug susceptibility testing
were noted as early as the early 1960s, when the principles
of the procedures currently in place were ﬁrst established.
‘We consider that the best type of sensitivity test is a fully
quantitative determination in which the organisms’ capability
of growth on medium containing a wide range of drug con-
centrations is known. This type of test would provide full
information on the degree of resistance. However, since
such a test requires large amounts of medium and is time-
consuming, it cannot be recommended as a routine proce-
dure’ [3]. Nevertheless, achieving this aim is more relevant
than ever; the emergence and rise of drug-resistant TB has
created an urgent need to make optimal use of the available
drugs. The consequences of possibly erratic drug susceptibil-
ity testing are particularly severe in terms of treatment
options for apparent MDR or XDR TB. Following 40 years
of proportion-based testing at critical concentrations, and in
view of the techniques available today, it may be time to
adapt mycobacterial drug susceptibility testing to standard
bacteriology procedures. Although critical concentration
testing is certainly appropriate for screening and for recog-
nizing any changes in wild-type drug susceptibility, it should
be supplemented by measures of quantitative drug suscepti-
bility in cases of test results showing resistance, in particular
for those drugs for which heterogeneity in phenotypic resis-
tance is frequently present.
In conclusion, the term ‘resistance’ with regard to
M. tuberculosis is by no means a simple homogeneous cate-
gory, but is quite heterogeneous and frequently composed
of low-level, moderate-level and high-level drug resistance.
This presumably has important biological implications. It is
conceivable that low-level drug resistance, in part, does not
correspond to clinical resistance; conversely, in the presence
of a high-level resistance phenotype, the drug is of little, if
any, clinical beneﬁt. The clinical implications of moderate lev-
els of resistance are less clear, and need to be addressed
more fully in future studies taking into account PK/PD
parameters. However, changes in our methods for drug sus-
ceptibility testing are required to address these issues. Most
important are standardized protocols for quantitative drug
susceptibility testing of both ﬁrst-line and second-line drugs
as a prerequisite for prospective studies addressing the
impact of resistance heterogeneity on treatment results, i.e.
by correlating data from quantitative resistance testing with
clinical outcome. Given the limited number of drugs available
for the management of XDR TB, it is essential to take
advantage of those that could possibly be used in a multi-
drug regimen to treat a signiﬁcant proportion of corre-
sponding cases.
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